KR100882611B1 - 표적 리간드로서 폴릭산이 도입된 유전자 전달체용저분자량 수용성 키토산 나노입자 및 이의 제조방법 - Google Patents
표적 리간드로서 폴릭산이 도입된 유전자 전달체용저분자량 수용성 키토산 나노입자 및 이의 제조방법 Download PDFInfo
- Publication number
- KR100882611B1 KR100882611B1 KR1020060112418A KR20060112418A KR100882611B1 KR 100882611 B1 KR100882611 B1 KR 100882611B1 KR 1020060112418 A KR1020060112418 A KR 1020060112418A KR 20060112418 A KR20060112418 A KR 20060112418A KR 100882611 B1 KR100882611 B1 KR 100882611B1
- Authority
- KR
- South Korea
- Prior art keywords
- soluble chitosan
- low molecular
- gene
- molecular weight
- water
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
- C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nanotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Physics & Mathematics (AREA)
- Composite Materials (AREA)
- Medical Informatics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
구분 | 탈아세틸화도(%) | 치환도(%) |
실시예1 | 96.38 | 2.48 |
실시예2 | 96.29 | 4.20 |
실시예3 | 96.33 | 9.22 |
실시예4 | 96.12 | 13.74 |
Claims (18)
- 삭제
- 삭제
- 삭제
- 삭제
- 제5항에 있어서, 상기 수용성 키토산 나노입자와 유전자가 1:2 ~ 1:50의 무게 비율로 구성되는 수용성 키토산 유전자 복합체.
- 제5항 또는 제6항에 있어서, 상기 유전자가 DNA인 것인 수용성 키토산 유전자 복합체.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 제15항에 있어서, 상기 수용성 키토산 나노입자와 유전자가 1:2 ~ 1:50의 무 게 비율로 구성되는 유전자 전달체용 수용성 키토산 유전자 복합체의 제조방법.
- 제15항에 있어서, 상기 유전자는 DNA인 것인 유전자 전달체용 수용성 키토산 유전자 복합체의 제조방법.
- 제15항에 있어서, 상기 유전자 전달체용 수용성 키토산 나노입자는 50 nm ~ 250 nm 범위의 크기를 갖는 유전자 전달체용 수용성 키토산 유전자 복합체의 제조방법.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060112418A KR100882611B1 (ko) | 2006-11-14 | 2006-11-14 | 표적 리간드로서 폴릭산이 도입된 유전자 전달체용저분자량 수용성 키토산 나노입자 및 이의 제조방법 |
PCT/KR2007/005711 WO2008060096A1 (en) | 2006-11-14 | 2007-11-14 | Low-molecular weight, water-soluble chitosan nanoparticle for gene delivery with folic acid conjugaed thereto as target ligand and preparation method thereof |
US12/514,351 US20100040694A1 (en) | 2006-11-14 | 2007-11-14 | Low-molecular weight, water-soluble chitosan nanoparticle for gene delivery with folic acid conjugaed thereto as target ligand and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060112418A KR100882611B1 (ko) | 2006-11-14 | 2006-11-14 | 표적 리간드로서 폴릭산이 도입된 유전자 전달체용저분자량 수용성 키토산 나노입자 및 이의 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20080043638A KR20080043638A (ko) | 2008-05-19 |
KR100882611B1 true KR100882611B1 (ko) | 2009-02-12 |
Family
ID=39401861
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060112418A KR100882611B1 (ko) | 2006-11-14 | 2006-11-14 | 표적 리간드로서 폴릭산이 도입된 유전자 전달체용저분자량 수용성 키토산 나노입자 및 이의 제조방법 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20100040694A1 (ko) |
KR (1) | KR100882611B1 (ko) |
WO (1) | WO2008060096A1 (ko) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2621018T3 (es) | 2007-02-19 | 2017-06-30 | Marine Polymer Technologies, Inc. | Composiciones hemostáticas y regímenes terapéuticos |
MX342912B (es) | 2010-04-15 | 2016-10-19 | Marine Polymer Tech Inc | Aplicaciones antibacterianas de nanofibras de poli-n-acetilglucosamina. |
AU2013203247A1 (en) * | 2010-11-06 | 2013-05-09 | Marine Polymer Technologies, Inc. | Compositions and methods for nanopolymer-based nucleic acid delivery |
US20140127310A1 (en) | 2011-04-15 | 2014-05-08 | Marine Polymer Technologies, Inc. | Treatment of disease with poly-n-acetylglucosamine nanofibers |
KR101383324B1 (ko) | 2011-11-10 | 2014-04-28 | 주식회사 종근당 | 신규한 유전자 전달용 조성물 |
KR101601035B1 (ko) | 2013-02-28 | 2016-03-08 | 주식회사 종근당 | 키토산 및 액상결정 형성 물질을 포함하는 유전자 전달용 조성물 |
RU2642786C2 (ru) * | 2015-01-30 | 2018-01-26 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Стабилизатор липосомальных суспензий |
US9862780B1 (en) | 2017-01-24 | 2018-01-09 | Jordan University Of Science And Technology | Process of producing and method of using soluble high molecular-weight chitosan |
CN107375940B (zh) * | 2017-07-18 | 2020-11-03 | 福州大学 | 以粘附因子icam-1为靶点的纳米药物制备及其应用 |
KR102604038B1 (ko) * | 2021-05-07 | 2023-11-20 | 주식회사 키토라이프 | 트로폴론이 담지된 키토산 나노입자 및 이의 제조방법 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5736532A (en) | 1996-02-14 | 1998-04-07 | Furda; Ivan | Multifunctional fat absorption and blood cholesterol reducing formulation comprising chitosan |
US6130321A (en) | 1998-07-10 | 2000-10-10 | Vanson, Inc. | High tap density chitosan, and methods of production |
US6323189B1 (en) | 1998-07-30 | 2001-11-27 | E-Nutriceuticals, Inc. | Chitosan-containing liquid compositions and methods for their preparation and use |
US20060105049A1 (en) * | 2004-11-12 | 2006-05-18 | Valorisation Recherche Hscm & Universite De Montreal | Folic acid-chitosan-DNA nanoparticles |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6184037B1 (en) * | 1996-05-17 | 2001-02-06 | Genemedicine, Inc. | Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell |
US7345165B2 (en) * | 2001-09-25 | 2008-03-18 | Jae Woon Nah | Method for preparing water-soluble free amine chitosan |
FR2841137B1 (fr) * | 2002-06-20 | 2004-08-13 | Bioalliance Pharma | Systeme de vectorisation comprenant des nanoparticules de taille homogene d'au moins un polymere et d'au moins un polysaccharide charge positivement |
-
2006
- 2006-11-14 KR KR1020060112418A patent/KR100882611B1/ko active IP Right Grant
-
2007
- 2007-11-14 US US12/514,351 patent/US20100040694A1/en not_active Abandoned
- 2007-11-14 WO PCT/KR2007/005711 patent/WO2008060096A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5736532A (en) | 1996-02-14 | 1998-04-07 | Furda; Ivan | Multifunctional fat absorption and blood cholesterol reducing formulation comprising chitosan |
US6130321A (en) | 1998-07-10 | 2000-10-10 | Vanson, Inc. | High tap density chitosan, and methods of production |
US6323189B1 (en) | 1998-07-30 | 2001-11-27 | E-Nutriceuticals, Inc. | Chitosan-containing liquid compositions and methods for their preparation and use |
US20060105049A1 (en) * | 2004-11-12 | 2006-05-18 | Valorisation Recherche Hscm & Universite De Montreal | Folic acid-chitosan-DNA nanoparticles |
Also Published As
Publication number | Publication date |
---|---|
WO2008060096A1 (en) | 2008-05-22 |
US20100040694A1 (en) | 2010-02-18 |
KR20080043638A (ko) | 2008-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100882611B1 (ko) | 표적 리간드로서 폴릭산이 도입된 유전자 전달체용저분자량 수용성 키토산 나노입자 및 이의 제조방법 | |
Liang et al. | pH-responsive injectable hydrogels with mucosal adhesiveness based on chitosan-grafted-dihydrocaffeic acid and oxidized pullulan for localized drug delivery | |
Ahmad et al. | Recent advancement and development of chitin and chitosan-based nanocomposite for drug delivery: Critical approach to clinical research | |
Nangare et al. | Pharmaceutical applications of citric acid | |
Chen et al. | Recent advances in epsilon-poly-L-lysine and L-lysine-based dendrimer synthesis, modification, and biomedical applications | |
Allawadhi et al. | Biomedical applications of polysaccharide nanoparticles for chronic inflammatory disorders: Focus on rheumatoid arthritis, diabetes and organ fibrosis | |
CN102552105B (zh) | 一种级联脑部靶向药物递送***及其制备方法和用途 | |
KR101179471B1 (ko) | 자기 집합체 고분자 나노입자를 이용한 siRNA 전달 시스템 | |
Anirudhan et al. | Modified chitosan-hyaluronic acid based hydrogel for the pH-responsive Co-delivery of cisplatin and doxorubicin | |
CN110801431B (zh) | 一种核-壳型智能纳米递送***的构建及应用 | |
Shahzadi et al. | Facile synthesis of copolymerized cellulose grafted hydrogel doped calcium oxide nanocomposites with improved antioxidant activity for anti-arthritic and controlled release of doxorubicin for anti-cancer evaluation | |
JP2011524446A (ja) | ポリグリコールで修飾されたキトサンオリゴ糖脂肪酸グラフト体、その調製方法およびその使用 | |
CN104667289B (zh) | 一种抗肿瘤药物载体及其使用方法 | |
Elhassan et al. | Engineering hybrid nanosystems for efficient and targeted delivery against bacterial infections | |
Ehsanimehr et al. | Synthesis of pH-sensitive nanocarriers based on polyacrylamide grafted nanocrystalline cellulose for targeted drug delivery to folate receptor in breast cancer cells | |
CN105641710B (zh) | Ha/rgd修饰的靶向氧化石墨烯双载药复合材料制备方法 | |
CN113018251A (zh) | 一种具有pH和谷胱甘肽双重响应的双药物控释***及其制备方法 | |
KR100831391B1 (ko) | pH 민감성 이미다졸 그룹을 함유한 키토산 복합체 및 그제조방법 | |
Ganie et al. | Review on anti-cancer and anti-microbial applications of curdlan biomaterials | |
Roy et al. | Chitosan anchored nanoparticles in current drug development utilizing computer-aided pharmacokinetic modeling: case studies for target specific cancer treatment and future prospective | |
CN109464676B (zh) | 一种壳寡糖光敏靶向纳米粒的制备方法及产品 | |
KR101586866B1 (ko) | 약물 전달을 위한 pH-민감성 나노입자 및 이의 제조방법 | |
Verma et al. | 1, 3-Beta-Glucans: Drug Delivery and Pharmacology | |
Shariatinia | Functionalized chitosan in drug delivery | |
KR101447130B1 (ko) | 메톡시 폴리에틸렌글리콜이 그라프트된 키토산 공중합체에 메토트렉세이트가 담지된 고분자 미셀 및 이의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
N231 | Notification of change of applicant | ||
E90F | Notification of reason for final refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130201 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20140128 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20150130 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20160128 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20170203 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20180205 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20190102 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20191230 Year of fee payment: 12 |